This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/4/2026
Good morning, and welcome to the RIAM 3rd Quarter 2026 Earnings Conference Call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open to questions, with instructions to follow at that time. As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Cody LaCoste, Senior Manager of Investor Relations and Corporate Development. Thank you, Mr. LaCoste. You may begin.
Good morning and welcome to RIAM's third quarter 2026 earnings conference call. Joining me today are Dan Krawczyk, our President and Chief Executive Officer, and Marcus Moeltner, our Senior Vice President of Finance, Chief Financial Officer, and Treasurer. Last evening, we released our earnings report and accompanying presentation materials, which are available on our website at RIAM.com. During today's discussion, we may make forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially. These risks are outlined in our earnings release, SEC filings, and on slide two of the presentation. We will also reference certain non-GAAP financial measures to offer additional perspective on our operating performance. Reconciliations to the most directly comparable GAAP measures can be found in our presentation on slides 22 through 24. Thank you for joining us and for your continued interest in RIAM. I'll now turn the call over to Dan.
Thanks, Cody. Good morning, everyone, and thank you for joining us. Before getting into the quarter and our path forward, shareholders have asked me for my impression of the business and how we're positioning this business with participants in the strategic review. Therefore, I believe it's important to share the perspectives I've gained since I first spoke to you on the Q2 earnings call. More than ever, I'm convinced that Ryan Cellulose Specialties, or CS Franchise, is an incredible, valuable, and profitable business. But that value is being overshadowed by excess capacity filled with commodity products, which create ongoing losses within our high-purity cellulose, or HPC, business. The pricing dynamics make this clear. CS products have pricing power, but increased volume of lower-priced commodity products more than offset that strength. leaving the overall average cellulose pricing flat to declining. This translates into profit performance that understates the true value of the overall business. We clearly need to change our production mix to favor CS products. I am highly confident in our ability to unlock this value and deliver exceptional returns to our shareholders. My time with customers and at our facilities has strengthened my conviction in the value of our cellulose specialties business. Customers depend on RIAM's expertise to deliver product performance they cannot easily replicate elsewhere, including characteristics such as mouthfeel, reactivity, and color. Our products are specified into applications where those characteristics matter. We consistently transform a natural raw material with all its inherent variability into products with purity and technical characteristics customers need for their end products to perform as intended. That value also extends through their manufacturing processes where our reliable high purity products deliver higher yields, require less capital, and generate less waste than lower purity alternatives. Critical to our value proposition is that Ryan brings the innovation to our CS customers need to differentiate their products and deliver performance that sets them apart from their competitors. These customers operate at the highest levels of their markets where competition is fierce and innovation is critical to success. Our scientists understand cellulose at the molecular level and know how to translate that knowledge into production at scale to help our customers succeed. I saw this firsthand during customer visits when our discussions quickly turned to what we could achieve together and their ambitions for more sustainable future products. Built over many decades, these relationships rest on a deep understanding of customer requirements. They position Ryan to share in our customers' future success and enable us to evolve with changing markets. Our past pricing and biomaterial strategies enabled important successes and laid a foundation we can build on. However, those strategies did not resolve the fundamental imbalance in our production mix. We must and will address it promptly. Our priorities are now clear. Grow CS volumes, improve overall cellulose pricing by allocating a greater share of available capacity to CS, and execute tangible operating improvements at our mills. We must aggressively reduce the impact of commodity losses on the business. Our commercial team is working closely with customers to secure agreements that meet their future needs for reliable products performance and security of supply. We believe this renewed commitment and partnership will continue to grow and strengthen HPC. Growth is critical for our future performance, but we will not rely on growth alone. We are prepared to move aggressively to rebalance our production mix without sacrificing the value our products command in the market. These opportunities to unlock this business's value are primarily within our control and are central to our discussions with interested parties in the strategic review. That does not mean decisions about the outcome of the strategic review have already been made. They have not. We are strengthening the business and positioning RIAM to succeed under any review outcome and will be ready to execute. Turning to slide five. I'm engaging as part of the strategic review with interested parties who share my conviction in the potential of this business and recognize the opportunity to build on our strengths. Our ambition is to transform Ryan from a volatile, low-margin business constrained by the capital demands of its asset footprint and financial structure into a focused, high-margin, cellular specialty enterprise. Highly engineered products must anchor more predictable earnings supported by a footprint and financial structure that enable us to generate cash flow, reinvest in our future, and build lasting value for our shareholders. Turning to slide six. Our investment thesis is grounded in demonstrated performance. Pricing improvements in our cellulose specialty franchise have driven some of its strongest results since the Tembeck acquisition. The chart illustrates the price premium CS commands over commodity cellulose, or CC. In Q3, CS pricing was $2,227 per metric ton, compared with $825 per CC, a premium of 170%. G.P. Foley's late 2023 closure and Tamiska Means' 2024 HPC idling tightened supply, reinforcing our pricing leadership strategy. Commodity markets operate differently. Pricing is driven by supply and demand and not the differentiated product characteristics that support CS value. New entrants have repeatedly added commodity capacity, putting pressure on industry economics and creating volatility in our results. I ask that utilization alone is not enough. We must fill more of the available capacity with higher value CS products to unlock the franchise's earning potential. Turning to slide seven, reducing commodity exposure is not a marginal adjustment. It is a fundamental shift in how we create shareholder value. The impact extends beyond lost EBITDA. The losses materially depress consolidated margins and absorb profits from our specialty business. Less commodity exposure can reduce earnings volatility, improve predictability, and make the contribution of CS more visible in our results. A strategy that delivers better quality earnings supports a stronger valuation and a better outcome for shareholders through the strategic review. We are not pursuing volume for its own sake. We are pursuing a stronger earnings profile and a business that captures more of the value it creates. Turning to slide eight. Ryan delivered another strong quarter in HPC. Earnings and total cellular shipments improved sequentially, continuing the progress we have made since the first quarter. We also generated positive free cash flow. Construction is also underway on the Altamaha Green Energy or AGE project at Jessup, another example of creating long-term value from our existing infrastructure. Marcus will take you through the results in a few minutes. Before we get into that detail, I want to address the strategic review. I know shareholders are looking for a conclusion and I want to explain both the progress we have made and the current expectations around timing. The review is well advanced. Interested parties have visited our plants and detailed diligence has progressed well. Our team and advisors continue to work through follow-up information requests and discussions with those parties. That work includes helping them understand the value of the CS franchise and the commercial and operating opportunities we see in the business. This process is a top priority, and I am directly involved with interested parties. The Board's mandate to me is to maximize shareholder value. We are singularly focused on that objective, including managing our business for future success and discussing strategic alternatives to strengthen our CS franchise more quickly. The U.S. tariff on Canadian paperboard and resulting economic idling of temiscamine have caused a delay in the review timeline. I'll discuss that situation in more detail on slide 9. We no longer expect to conclude the review in the fourth quarter. We are targeting a conclusion of the strategic review in Q1 2027. I know this news is frustrating to you. It is frustrating to me as well. But I assure you, we continue to advance the process to bring this review to a successful conclusion and move forward on a path that maximizes value for shareholders. Turning to Tomiskamine on slide nine. The 50% U.S. tariff on Canadian paperboard took effect on August 22nd. Historically, approximately 70% of the site's paperboard production shipped to the U.S. That level of exposure made the tariff a significant change to the site's economics. We took mitigation steps during the third quarter, but despite those efforts, continued paperboard and high-yield pulp production was uneconomic. We economically idled production on October 3rd, and it remains idled. Essential site services continue to operate. We incurred $2 million in tariff-related costs during the third quarter. With production now idle, We estimate ongoing site carrying costs of $2 to $3 million per month. Our immediate focus is on managing those costs while evaluating all strategic options and working toward a definitive path forward for temiscamine. Interested parties need to understand the potential path forward for temiscamine, the ongoing costs, and the implications for the rest of the business. The conditions they are evaluating have changed. Our team has had to devote additional time and resources to managing the idling, evaluating the site's options, and providing the information and analysis needed to support that assessment. Together with the additional diligence parties are undertaking on temiscaming, that work has slowed the review. We are working through those questions with interested parties and our advisors while diligence and discussions on the broader business continue. Parties remain engaged. giving them a clear understanding of temiscamine and the options for the site is a critical part of maximizing value through the review. We want their assessment to reflect the full value of RIAM and the opportunities we see across the business. On slide 10, our priorities bring together the work on the business and the strategic review. First, advance the strategic review with interested parties and target a conclusion in Q1, 2027. Second, execute our cellular specialties leadership strategy. That means stronger customer partnerships, growing CS volumes, and capturing the value our products provide, supported by a production mix more heavily weighted towards CS and continued improvement in plant performance. Third, build on the sequential progress and work towards positive free cash flow for 2026. Achieving that objective requires disciplined working capital management Capital Spending, and Cost Control, and remain subject to tariff-related cash impacts and Tomiskamine's carrying costs. And fourth, exit 2026 with momentum. The progress in HPC continues to build and give us a better foundation. We need to build on that progress while managing Tomiskamine's impact and preserving financial flexibility as we enter 2027. With that, I'll turn it over to Marcus to walk through the quarter. are segment performance and balance sheet. I'll come back in slide 15 to discuss work underway as we look towards 2027.
You're reading a preview of the RYAM Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing